Lexeo Therapeutics' CEO on using gene therapy for cardiovascular and Alzheimer's disease
Noland Townsend describes the science behind Lexeo's lead programs, including ones in the clinic for APOE4 homozygous patients and Friedreich’s Ataxia cardiomyopathy.
Comments